全文获取类型
收费全文 | 1228篇 |
免费 | 81篇 |
国内免费 | 6篇 |
专业分类
耳鼻咽喉 | 26篇 |
儿科学 | 25篇 |
妇产科学 | 18篇 |
基础医学 | 152篇 |
口腔科学 | 34篇 |
临床医学 | 76篇 |
内科学 | 347篇 |
皮肤病学 | 31篇 |
神经病学 | 46篇 |
特种医学 | 15篇 |
外科学 | 203篇 |
综合类 | 32篇 |
一般理论 | 1篇 |
预防医学 | 81篇 |
眼科学 | 43篇 |
药学 | 91篇 |
中国医学 | 29篇 |
肿瘤学 | 65篇 |
出版年
2023年 | 6篇 |
2022年 | 12篇 |
2021年 | 36篇 |
2020年 | 27篇 |
2019年 | 61篇 |
2018年 | 47篇 |
2017年 | 30篇 |
2016年 | 30篇 |
2015年 | 27篇 |
2014年 | 42篇 |
2013年 | 75篇 |
2012年 | 93篇 |
2011年 | 119篇 |
2010年 | 49篇 |
2009年 | 44篇 |
2008年 | 64篇 |
2007年 | 74篇 |
2006年 | 53篇 |
2005年 | 55篇 |
2004年 | 57篇 |
2003年 | 45篇 |
2002年 | 34篇 |
2001年 | 21篇 |
2000年 | 29篇 |
1999年 | 24篇 |
1998年 | 7篇 |
1997年 | 3篇 |
1995年 | 5篇 |
1994年 | 7篇 |
1992年 | 10篇 |
1991年 | 12篇 |
1990年 | 6篇 |
1989年 | 12篇 |
1988年 | 10篇 |
1987年 | 9篇 |
1986年 | 11篇 |
1985年 | 5篇 |
1984年 | 3篇 |
1983年 | 5篇 |
1979年 | 8篇 |
1977年 | 2篇 |
1975年 | 5篇 |
1974年 | 8篇 |
1973年 | 2篇 |
1972年 | 3篇 |
1971年 | 2篇 |
1970年 | 3篇 |
1969年 | 5篇 |
1968年 | 5篇 |
1967年 | 4篇 |
排序方式: 共有1315条查询结果,搜索用时 312 毫秒
1.
2.
Abhyuday Kumar Neeraj Kumar Dharani Lenin Amarjeet Kumar Shaheen Ahmad 《Indian Journal of Critical Care Medicine》2021,25(4):474
How to cite this article: Kumar A, Kumar N, Lenin D, Kumar A, Ahmad S. Second-degree Heart Block Caused by Itolizumab-induced Infusion Reaction in COVID-19. Indian J Crit Care Med 2021;25(4):474–475.Sir,Itolizumab, an anti-CD6 humanized IgG1 monoclonal antibody, binds to domain-1 of CD-6 that is responsible for priming, activation, and differentiation of T-cells.[1] It significantly reduces T-cell proliferation along with substantial downregulation of the production of cytokines/chemokines.1 It was approved for moderate to severe chronic plaque psoriasis in 2013. However, it has recently been approved by the Drug Controller General of India for emergency use in India for the treatment of cytokine release syndrome in moderate to severe acute respiratory distress syndrome patients due to COVID-19.2 Here, we report a case of life-threatening infusion-related hypersensitivity reaction of itolizumab.A 65-year-old male COVID-19 patient got admitted to the intensive care unit (ICU) with complaints of shortness of breath and cough without any history of known disease. However, the baseline electrocardiogram (ECG) done in the ICU was suggestive of left bundle branch block (LBBB) (Fig. 1A). The patient was supported through noninvasive ventilation (NIV) and was started on remdesivir, dexamethasone, low-molecular-weight heparin, antibiotics, and other supportive treatment as per our institutional standard protocol. The patient was maintaining on continuous positive airway pressure mode of NIV with a fraction of inspired oxygen (FiO2) of 0.5 on the third day of ICU admission. Among the laboratory markers, the total leucocyte counts were raised (12,000/μL) with decreased lymphocytes (3.2%) and increased inflammatory markers (CRP, 320 mg/L; D dimer >20 μg/mL; LDH, 1694 U/L; IL6, 329 pg/mL). Serum electrolytes, renal function tests, liver function tests, and arterial blood gases were within acceptable limits. The patient was hemodynamically stable with a respiratory rate of 30 to 35/minute and a PO2/FiO2 ratio of 140. After taking informed written consent, inj. itolizumab was planned in this patient because of the increasing severity of the disease along with increased inflammatory markers. Inj. hydrocortisone 100 mg IV and inj. pheniramine 30 mg IV were given 30 minutes before itolizumab infusion. And 100 mg of itolizumab (Alzumab-L, Biocon Biologics) was diluted to 250 mL with normal saline and was started at 25 mL/hour. After about 20 minutes of infusion, the patient started complaining of shivering, sweating, and impending doom. The patient had sudden bronchospasm, and oxygen saturation dropped to 90%. ECG showed second-degree AV nodal block with an increased blood pressure of 180/110 mm Hg (Fig. 1B). The drug was immediately withdrawn and the patient was given a repeat dose of hydrocortisone and pheniramine along with other supportive measures. After sometime patients became alert and their respiratory symptoms were relieved. However, the second-degree heart block in ECG was persistent. ECHO was normal and troponin I was within normal limits while there was a slight increase in CPK-MB. The patient was observed closely and the ECG reverted to its previous state only after 24 hours. The patient was weaned from the ventilator in due course of time and put on face mask on the eighth day of stay.Open in a separate windowFigs 1A and B(A) Baseline ECG showing LBBB; (B) ECG showing second-degree AV nodal block after infusion reactionMost infusion reactions related to monoclonal antibodies are IgE mediated and are mild (grade 1 or 2) in nature.3 The incidence of severe (grade 3 or 4) reactions is generally low. The reported infusion-related reactions to itolizumab are chills/rigors (common), nausea, flushing, urticaria, cough, hypersensitivity, pruritus, rash, wheezing, dyspnea, oxygen desaturation, dizziness, headache, and hypertension. In our case, itolizumab infusion leads to a grade 4 reaction causing a persistent second-degree heart block for about 24 hours. Among the monoclonal antibodies, rituximab is most notorious for causing infusion reactions.4 There are only a few reports of cardiac arrhythmias (monomorphic VT, supraventricular tachycardia, trigeminy, and irregular pulse) during therapeutic infusion of rituximab,5 and there is no reported case of cardiac arrhythmia during itolizumab infusion. In our case, the patient was having LBBB and was on a QT prolonging drug (remdesivir), which might be a predisposing factor for the occurrence of second-degree heart block during infusion reaction. Premedications (e.g., antipyretics, antihistamines, and steroids) are recommended before the administration of some chemotherapeutic agents and monoclonal antibodies. These drugs should never be given as IV bolus and should always be given slowly in an infusion. Baseline assessments including vital signs and cognition should be documented carefully before the start of treatment and all the emergency equipment and drugs should be kept ready. Grade 3 and 4 reactions should be managed promptly with epinephrine, antihistaminics, and steroids along with other symptomatic supportive measures. As itolizumab is approved for emergency use in COVID-19, risk-benefit ratio should be assessed before prescribing this and should be explained before taking consent for infusion.The patient provided written informed consent for the publication. 相似文献
3.
4.
Mohammed Arshad Ali Jalal Syed Shafiuddin Shaheen Mohammed Ali Khan 《Indian Journal of Critical Care Medicine》2014,18(2):107-109
Thrombotic thrombocytopenic purpura (TTP) is a rare syndrome of unknown cause with an estimated incidence of one case per million. The disease is characterized by a pentad of symptoms: Thrombocytopenia, microangiopathic hemolytic anemia, neurologic changes, renal dysfunction, and fever. It causes thrombosis in the microvasculature of several organs, producing diverse manifestations. Acute pancreatitis (AP) is a well-described consequence of TTP. Acute pancreatitis triggering TTP is uncommon. 相似文献
5.
N H El-Mangoury S I Shaheen Y A Mostafa 《American journal of orthodontics and dentofacial orthopedics》1987,91(1):57-61
A lack of cognition regarding the reliability of landmark identification in posteroanterior cephalometrics keeps the extracted data questionable. The present study was designed to analyze this problem for the purpose of providing certain insights. An interactive computer graphic package was developed. This package was called EA-PAX (Error Analysis of Postero-Anterior cephalometric X-ray films). A random sample of 40 clear posteroanterior cephalometric head plates was studied. The reliability of landmark identification was established. The skeletal landmarks seemed more reliable than the dental landmarks. The variation in the direction and magnitude of the error was determined for each landmark. Most landmarks had their own characteristic noncircular envelope of error. It is not the philosophy of the present authors to tell the orthodontists what to use. Rather, the philosophy is to be aware of the amount and direction of variation for a particular landmark. Taking this into consideration will enable the orthodontists to look on their cephalometric numbers with a mental awareness of the possible variations. Several clinical and research studies are suggested in the article. 相似文献
6.
N. Patel A.O. Khan S. Alsahli G. Abdel‐Salam S.R. Nowilaty A.M. Mansour A. Nabil M. Al‐Owain S. Sogati M.A. Salih A.M. Kamal H. Alsharif H.S. Alsaif S.S. Alzahrani F. Abdulwahab N. Ibrahim M. Hashem T. Faquih Z.A. Shah M. Abouelhoda D. Monies M. Dasouki R. Shaheen S.M. Wakil M.A. Aldahmesh F.S. Alkuraya 《Clinical genetics》2018,93(6):1210-1222
Microphthalmia is a developmental eye defect that is highly variable in severity and in its potential for systemic association. Despite the discovery of many disease genes in microphthalmia, at least 50% of patients remain undiagnosed genetically. Here, we describe a cohort of 147 patients (93 families) from our highly consanguineous population with various forms of microphthalmia (including the distinct entity of posterior microphthalmos) that were investigated using a next‐generation sequencing multi‐gene panel (i‐panel) as well as whole exome sequencing and molecular karyotyping. A potentially causal mutation was identified in the majority of the cohort with microphthalmia (61%) and posterior microphthalmos (82%). The identified mutations (55 point mutations, 15 of which are novel) spanned 24 known disease genes, some of which have not or only very rarely been linked to microphthalmia (PAX6, SLC18A2, DSC3 and CNKSR1). Our study has also identified interesting candidate variants in 2 genes that have not been linked to human diseases (MYO10 and ZNF219), which we present here as novel candidates for microphthalmia. In addition to revealing novel phenotypic aspects of microphthalmia, this study expands its allelic and locus heterogeneity and highlights the need for expanded testing of patients with this condition. 相似文献
7.
Hanan E. Shamseldin Ranad Shaheen Nour Ewida Dalal K. Bubshait Hisham Alkuraya Elham Almardawi Ali Howaidi Yasser Sabr Ebtesam M. Abdalla Abdullah Y. Alfaifi Jameel Mohammed Alghamdi Afaf Alsagheir Ahmed Alfares Heba Morsy Maged H. Hussein Mohammad A. Al-Muhaizea Mohammad Shagrani Essam Al Sabban Fowzan S. Alkuraya 《Genetics in medicine》2022,24(4):966
8.
9.
10.
The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population‐based estimates from Denmark 下载免费PDF全文